Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Express Scripts
Merck
Harvard Business School
Medtronic

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for betamethasone dipropionate; calcipotriene and what is the scope of freedom to operate?

Betamethasone dipropionate; calcipotriene is the generic ingredient in three branded drugs marketed by Leo Pharma As, Perrigo Uk Finco, and Tolmar, and is included in five NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Betamethasone dipropionate; calcipotriene has one hundred and thirty-one patent family members in thirty-six countries.

There are sixty-six drug master file entries for betamethasone dipropionate; calcipotriene. Three suppliers are listed for this compound.

Recent Clinical Trials for BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Psoriasis Treatment Center of Central New JerseyPhase 4
Celgene CorporationPhase 4
Icahn School of Medicine at Mount SinaiPhase 4

See all BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE clinical trials

Recent Litigation for BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

Identify potential future generic entrants

District Court Litigation
Case NameDate
LEO Pharma A/S v. Tolmar Inc.2010-04-06

See all BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE litigation

Pharmacology for BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE
Paragraph IV (Patent) Challenges for BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE
Tradename Dosage Ingredient NDA Submissiondate
TACLONEX OINTMENT;TOPICAL betamethasone dipropionate; calcipotriene 021852 2010-03-31

US Patents and Regulatory Information for BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene SUSPENSION;TOPICAL 022185-001 May 9, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene SUSPENSION;TOPICAL 022185-001 May 9, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Leo Pharma As ENSTILAR betamethasone dipropionate; calcipotriene AEROSOL, FOAM;TOPICAL 207589-001 Oct 16, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene SUSPENSION;TOPICAL 022185-001 May 9, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
Leo Pharma As ENSTILAR betamethasone dipropionate; calcipotriene AEROSOL, FOAM;TOPICAL 207589-001 Oct 16, 2015 RX Yes Yes   Start Trial   Start Trial   Start Trial
Leo Pharma As ENSTILAR betamethasone dipropionate; calcipotriene AEROSOL, FOAM;TOPICAL 207589-001 Oct 16, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene SUSPENSION;TOPICAL 022185-001 May 9, 2008   Start Trial   Start Trial
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene OINTMENT;TOPICAL 021852-001 Jan 9, 2006   Start Trial   Start Trial
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene OINTMENT;TOPICAL 021852-001 Jan 9, 2006   Start Trial   Start Trial
Leo Pharma As TACLONEX betamethasone dipropionate; calcipotriene OINTMENT;TOPICAL 021852-001 Jan 9, 2006   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Medtronic
Dow
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.